Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Lynparza for Ovarian Cancer

FDA news release; 2017 Aug 17

The FDA has approved Lynparza (olaparib) for the maintenance treatment of patients with ovarian cancer.

Indications: Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

Dosage and administration: 300 mg taken orally twice daily with or without food.

Efficacy and safety: Approval is based on results of 2 randomized, placebo-controlled, double-blind, multicenter trials which demonstrated statistically significant improvement in progression-free survival in patients receiving Lynparza, vs those treated with placebo.

Side effects/risks: The most common adverse reactions are anemia, nausea, fatigue, vomiting, nasopharyngitis/upper respiratory tract infection/influenza, diarrhea, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation, and stomatitis.


FDA approves olaparib tablets for maintenance treatment in ovarian cancer [news release]. Silver Spring, MD: FDA. August 17, 2017. Accessed August 27, 2017.

Lynparza [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 2017. Accessed August 27, 2017.

This Week's Must Reads

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018

Must Reads in FDA Actions

Nivolumab plus ipilimumab approved for advanced RCC, FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma

FDA Approves Lynparza for Certain Types of BC, FDA news release; 2018 Jan 12

Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22

Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20

Varubi Approved for Delayed Nausea and Vomiting, Tesaro news release; 2017 Oct 25